EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effects of Low-dose Methotrexate With Methimazole in Patients With Graves’ Disease: Results of a Randomized Clinical Trial

Pu Xie iD, Liyun Shen, Rongguang Peng, Yanqiu Wang, Qinglei Yin, Xinxin Chen, Zhou Jin, Guang Ning iD, Weiqing Wang iD, Shu Wang iD, Yulin Zhou iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae472 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Pu Xie und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong Universit…. Hauptthemen laut MEDLINE: Methimazole, Methotrexate, Graves Disease, Antithyroid Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Supplemental methotrexate (MTX) may affect the clinical course of Graves’ disease (GD).

Objective

To evaluate the efficacy of add-on MTX on medical treatment in GD.

Design

Prospective, open-label, randomized supplementation controlled trial.

Setting

Academic endocrine outpatient clinic. Patients One hundred fifty-three untreated hyperthyroid patients with GD.

Intervention

Patients received MTX 10 mg/w with methimazole (MMI) or MMI only. MTX and MMI were discontinued at months 12 to 18 in euthyroid patients. Main Outcome Measures Discontinuation rate at month 18 in each group.

Results

In the MTX with MMI group, the discontinuation rate was higher than the MMI group at months 15 to 18 [50.0 vs 33.3%, P = .043, 95% confidence interval (CI) 1.020-3.922; and 55.6 vs 38.9%, P = .045, 95% CI 1.011-3.815, respectively). The decrease in thyrotropin-related antibodies (TRAb) levels in the MTX with MMI group was significant from baseline to month 6 compared to the MMI alone group [MTX + MMI 67.22% (43.12-80.32), MMI 54.85% (33.18-73.76), P = .039] and became more significant from month 9 [MTX + MMI 77.79% (62.27-88.18), MMI 69.55% (50.50-83.22), P = .035] to month 18 (P < .01 in 15-18 months). A statistically significant difference was seen between the levels of TRAb in the MTX with MMI group and the MMI group at 9 to 18 months. There were no significant differences in the levels of free T3, free T4, and TSH between the 2 groups. No serious drug-related adverse events were observed in either group (P = .771).

Conclusion

Supplemental MTX with MMI resulted in a higher discontinuation rate and improvement in decreased TRAb levels to homeostatic levels faster than methimazole treatment alone at months 12 to 18.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethimazoleMethotrexateGraves DiseaseAntithyroid AgentsHumansFemaleMaleAdultMiddle AgedDrug Therapy, CombinationTreatment OutcomeProspective StudiesAged

Stichwörter der Autor:innen

Graves’ diseaseMTXTRAbautoimmunityclinical trialmethotrexate

Substanzen

MethimazoleMethotrexateAntithyroid Agents

Autor:innen und Institutionen

  • Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  • Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruij…
  • Guangdong Geriatric Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510000, China.
  • Department of Endocrine and Metabolic Diseases, The Affiliated Suzhou Hospital of Nanjing Medical University, 26 Daoqian Road, Suzhou 215000, China.

ORCID-Profile: Pu Xie, Guang Ning, Weiqing Wang, Shu Wang, Yulin Zhou

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xie, P., Shen, L., Peng, R., Wang, Y., Yin, Q., Chen, X., Jin, Z., Ning, G., Wang, W., Wang, S., & Zhou, Y. (2025). Effects of Low-dose Methotrexate With Methimazole in Patients With Graves’ Disease: Results of a Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae472

Vancouver

Xie P, Shen L, Peng R, Wang Y, Yin Q, Chen X, et al. Effects of Low-dose Methotrexate With Methimazole in Patients With Graves’ Disease: Results of a Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae472

BibTeX
@article{Xie2025,
  author = {Xie, Pu and Shen, Liyun and Peng, Rongguang and Wang, Yanqiu and Yin, Qinglei and Chen, Xinxin and Jin, Zhou and Ning, Guang and Wang, Weiqing and Wang, Shu and Zhou, Yulin},
  title = {Effects of Low-dose Methotrexate With Methimazole in Patients With Graves’ Disease: Results of a Randomized Clinical Trial},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae472}
}
Kostenlos starten →